Flash Note



Indusind Bank

Refer to important disclosures at the end of this report

CMP
Rs 1,156

Target Price Rs 1,275 (■)

Rating Upside BUY (■) 10.3 %

Strong, in-line growth; Management uncertainty largely behind

Business Update - Q2FY23

- IndusInd Bank's (IIB's) credit growth remains robust and in line with our expectations, at 18% YoY/5% QoQ in Q2FY23 which we believe is mainly driven by continued acceleration in the retail book (including MFI/CV) as well as the corporate book.
- On its MFI book (Bharat Financial, BFIL), the bank seems well poised for growth, with MFI as a sector being on the cusp of a growth-rebound, given asset-quality issues being largely behind and on-the-ground demand showing strong signs of pick-up. For IIB, entry into the higher-ticket individual MFI loan segment would also boost growth.
- Deposit growth too has been healthy for IIB, at 15% YoY/5% QoQ, unlike other banks', leading to nearly stable LDR at 82% in Q2. We expect margins to remain largely flattish in Q2, mainly due to flat LDR and repricing benefit to come with a lag owing to the bank's relatively higher fixed-rate asset book.
- We expect slippages to remain elevated on account of relapse in the restructured pool, but NPA ratios to moderate from Q1 levels on the back of better recovery and accelerating credit growth. Bank is also well-provided with specific PCR at 72% and additional contingent provision buffer at 0.8% of loans which should keep incremental LLP in check and, thus, be the key profit driver, apart from credit growth.
- We believe the MFI saga is largely behind and the recent term extension for the MD by the Board puts to rest the uncertainty about current MD&CEO Sumant Kathpalia's intention of continuing with the bank. We believe RBI approval for the MD re-appointment should not be a challenge, while re-accelerating credit growth, improving return ratios (13-16% over FY23-25E) and reasonable valuations (1.6x FY24E ABV) make IIB a compelling Buy.

Please see our sector model portfolio (Emkay Alpha Portfolio): BFSI-Banks

Financial Snapshot (Standalone)

•	,				
(Rs mn)	FY21	FY22	FY23E	FY24E	FY25E
Net income	200,865	223,979	249,599	286,895	335,735
Net profit	28,364	46,111	67,374	83,582	102,313
EPS (Rs)	36.7	59.5	86.9	107.8	132.0
ABV (Rs)	538.6	584.8	653.4	739.9	845.6
RoA (%)	0.8	1.2	1.6	1.7	1.8
RoE (%)	7.3	10.2	13.4	14.8	15.9
P/E (x)	33.3	20.5	14.0	11.3	9.2
P/ABV (x)	2.3	2.1	1.9	1.6	1.4

Source: Company, Emkay Research

Change in Estimates	
EPS Chg FY23E/FY24E (%)	-/-
Target Price change (%)	-
Target Period (Months)	12
Previous Reco	BUY

Emkay vs Consensus

EPS Estimates				
	FY23E	FY24E		
Emkay	86.9	107.8		
Consensus	91.0	111.7		
Mean Consensus TP (12	2M)	Rs 1,276		
Stock Details				
Bloomberg Code		IIB IN		
Face Value (Rs)		10		
Shares outstanding (mn)		775		
52 Week H/L	1	,276 / 763		
M Cap (Rs bn/USD bn)	8	96 / 10.95		
Daily Avg Volume (nos.)		4,373,332		
Daily Avg Turnover (USI) mn)	56.3		
Daily Avg Turnover (USI) mn)	56.3		

Shareholding Pattern Jun '22 Promoters 15.2% Fills 42.1% Dils 19.3% Public and Others 23.5%

Price Performance							
(%)	1M	3M	6M	12M			
Absolute	5	43	19	5			
Rel. to Nifty	9	34	28	10			

Relative price chart



Source: Bloomberg

This report is solely produced by Emkay Global. The following person(s) are responsible for the production of the recommendation:

Anand Dama

anand.dama@emkayglobal.com +91 22 6624 2480

Heet Khimawat

heet.khimawat@emkayglobal.com +91 22 6612 1275

Dixit Sankharva

dixit.sankharva@emkayglobal.com +91 22 6612 1281

Soumya Jain

soumya.jain@emkayglobal.com

This report is intended for team.emkay@whitemarquesolutions.com use and downloaded at 10/06/2#912226632*1262

Key Financials (Standalone)

Income Statement

Y/E Mar (Rs mn)	FY21	FY22	FY23E	FY24E	FY25E
Net interest income	135,279	150,008	172,364	199,195	234,514
Other income	65,586	73,970	77,235	87,700	101,222
Fee income	34,781	45,093	46,771	56,125	67,911
Net income	200,865	223,979	249,599	286,895	335,735
Operating expenses	83,598	95,593	110,465	126,808	147,507
Pre provision profit	117,267	128,386	139,134	160,087	188,229
PPP excl treasury	102,405	122,454	133,134	154,687	182,559
Provisions	79,425	66,650	49,061	48,346	51,446
Profit before tax	37,841	61,736	90,073	111,741	136,782
Tax	9,478	15,625	22,698	28,159	34,469
Tax rate (%)	25	25	25	25	25
Profit after tax	28,364	46,111	67,374	83,582	102,313

Balance Sheet

Y/E Year End (Rs mn)	FY21	FY22	FY23E	FY24E	FY25E
Equity	7,734	7,747	7,750	7,750	7,750
Reserves	425,866	469,065	528,117	597,608	682,349
Net worth	433,600	476,812	535,867	605,358	690,099
Deposits	2,562,050	2,936,813	3,381,913	4,038,217	4,869,142
Borrowings	458,329	405,333	384,417	424,158	467,874
Total liabilities	3,629,727	4,019,746	4,518,089	5,312,328	6,298,751
Cash and bank	178,707	156,412	187,694	225,233	270,279
Investments	696,947	709,708	839,517	972,385	1,110,270
Loans	2,125,954	2,390,515	2,803,870	3,368,757	4,081,399
Others	225,461	218,291	262,726	316,838	381,690
Total assets	3,629,727	4,019,746	4,518,089	5,312,328	6,298,751

Key Ratios (%)

Y/E Year End	FY21	FY22	FY23E	FY24E	FY25E
NIM	4.4	4.2	4.3	4.3	4.3
Non-II/avg assets	2.0	1.9	1.8	1.8	1.7
Fee income/avg assets	1.0	1.2	1.1	1.1	1.2
Opex/avg assets	2.5	2.5	2.6	2.6	2.5
Provisions/avg assets	2.4	1.7	1.1	1.0	0.9
PBT/avg assets	1.1	1.6	2.1	2.3	2.4
Tax/avg assets	0.3	0.4	0.5	0.6	0.6
RoA	8.0	1.2	1.6	1.7	1.8
RoAE	7.3	10.2	13.4	14.8	15.9
GNPA	2.7	2.3	2.0	1.8	1.6
NNPA	0.7	0.6	0.6	0.6	0.5

Per Share Data (Rs)	FY21	FY22	FY23E	FY24E	FY25E
EPS	36.7	59.5	86.9	107.8	132.0
BVPS	552.8	599.3	669.5	757.6	864.8
ABVPS	538.6	584.8	653.4	739.9	845.6
DPS	0.0	8.5	15.0	18.0	22.5

FY21	FY22	FY23E	FY24E	FY25E
33.3	20.5	14.0	11.3	9.2
2.2	2.0	1.8	1.6	1.4
2.3	2.1	1.9	1.6	1.4
7.5	6.9	6.3	5.5	4.7
0.0	0.7	1.3	1.6	1.9
	33.3 2.2 2.3 7.5	33.3 20.5 2.2 2.0 2.3 2.1 7.5 6.9	33.3 20.5 14.0 2.2 2.0 1.8 2.3 2.1 1.9 7.5 6.9 6.3	33.3 20.5 14.0 11.3 2.2 2.0 1.8 1.6 2.3 2.1 1.9 1.6 7.5 6.9 6.3 5.5

Source: Company, Emkay Research
This report is intended for team.emkay@whitemarquesolutions.com use and downloaded at 10/06/2022 02:26 PM

Growth (%)	FY21	FY22	FY23E	FY24E	FY25E
NII	12.2	10.9	14.9	15.6	17.7
PPOP	8.9	9.5	8.4	15.1	17.6
PAT	(35.8)	62.6	46.1	24.1	22.4
Loans	2.8	12.4	17.3	20.1	21.2

Quarterly (Rs mn)	Q1FY22	Q2FY22	Q3FY22	Q4FY22	Q1FY23
NII	35,637	36,584	37,936	39,852	41,253
NIM (%)	4.1	4.1	4.1	4.2	4.2
PPOP	31,855	32,187	33,121	33,814	34,307
PAT	10,161	11,467	12,414	14,005	16,310
EPS (Rs)	13.13	14.81	16.04	18.09	21.07

Source: Company, Emkay Research


Shareholding Pattern (%)	Jun-21	Sep-21	Dec-21	Mar-22	Jun-22
Promoters	15.2	15.2	15.2	15.2	15.2
FIIs	47.8	47.2	43.8	42.5	42.1
DIIs	16.3	17.4	18.6	20.1	19.3
Public and Others	20.7	20.2	22.5	22.2	23.5

Source: Capitaline

Date	Closing Price	TP	Period (months)	Rating	Analyst
28-Jul-22	1,018	1,275	12	Buy	Anand Dama
21-Jul-22	948	1,275	12	Buy	Anand Dama
1-May-22	979	1,350	12	Buy	Anand Dama
30-Jan-22	904	1,350	12	Buy	Anand Dama
7-Nov-21	1,189	1,460	12	Buy	Anand Dama
28-Oct-21	1,176	1,460	12	Buy	Anand Dama
5-Oct-21	1,169	1,375	12	Buy	Anand Dama
28-Jul-21	993	1,375	12	Buy	Anand Dama
22-Jun-21	1,000	1,375	12	Buy	Anand Dama
2-May-21	935	1,125	12	Buy	Anand Dama
30-Jan-21	846	1,175	12	Buy	Anand Dama
20-Jan-21	948	1,175	12	Buy	Anand Dama
31-Oct-20	586	660	12	Hold	Anand Dama
29-Sep-20	536	550	12	Hold	Anand Dama
29-Jul-20	551	550	12	Hold	Anand Dama
28-Apr-20	468	550	12	Buy	Anand Dama
11-Apr-20	395	630	12	Buy	Anand Dama
30-Mar-20	413	630	12	Buy	Anand Dama
14-Jan-20	1,482	1,725	12	Buy	Anand Dama
16-Dec-19	1,493	1,725	12	Buy	Anand Dama
10-Oct-19	1,229	1,500	12	Buy	Anand Dama
9-Oct-19	1,309	1,725	12	Buy	Anand Dama

Source: Company, Emkay Research

RECOMMENDATION HISTORY (Rs/share)



Source: Bloomberg, Company, Emkay Research

Emkay Rating Distribution

Ratings	Expected Return within the next 12-18 months.	
BUY	Over 15%	
HOLD	Between -5% to 15%	
SELL	Below -5%	

Completed Date: 04 Oct 2022 17:52:33 (SGT)
Dissemination Date: 04 Oct 2022 17:53:33 (SGT)

Sources for all charts and tables are Emkay Research unless otherwise specified.

GENERAL DISCLOSURE/DISCLAIMER BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):

Emkay Global Financial Services Limited (CIN-L67120MH1995PLC084899) and its affiliates are a full-service, brokerage, investment banking, investment management and financing group. Emkay Global Financial Services Limited (EGFSL) along with its affiliates are participants in virtually all securities trading markets in India. EGFSL was established in 1995 and is one of India's leading brokerage and distribution house. EGFSL is a corporate trading member of Bombay Stock Exchange Limited (BSE), National Stock Exchange of India Limited (NSE), MCX Stock Exchange Limited (MCX-SX). EGFSL along with its subsidiaries offers the most comprehensive avenues for investments and is engaged in the businesses including stock broking (Institutional and retail), merchant banking, commodity broking, depository participant, portfolio management, insurance broking and services rendered in connection with distribution of primary market issues and financial products like mutual funds, fixed deposits. Details of associates are available on our website i.e. www.emkavolobal.com

EGFSL is registered as Research Analyst with SEBI bearing registration Number INH000000354 as per SEBI (Research Analysts) Regulations, 2014. EGFSL hereby declares that it has not defaulted with any stock exchange nor its activities were suspended by any stock exchange with whom it is registered in last five years, except that NSE had disabled EGFSL from trading on October 05, October 08 and October 09, 2012 for a manifest error resulting into a bonafide erroneous trade on October 05, 2012. However, SEBI and Stock Exchanges have conducted the routine inspection and based on their observations have issued advice letters or levied minor penalty on EGFSL for certain operational deviations in ordinary/routine course of business. EGFSL has not been debarred from doing business by any Stock Exchange / SEBI or any other authorities; nor has its certificate of registration been cancelled by SEBI at any point of time.

EGFSL offers research services to clients as well as prospects. The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

Other disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) covered in this report

EGFSL and/or its affiliates may seek investment banking or other business from the company or companies that are the subject of this material. Our salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions that are contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that may be inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest including but not limited to those stated herein. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein. This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or which would subject EGFSL or its group companies to any registration or licensing requirement within such jurisdiction. Specifically, this document does not constitute an offer to or solicitation to any U.S. person for the purchase or sale of any financial instrument or as an official confirmation of any transaction to any U.S. person. Unless otherwise stated, this message should not be construed as official confirmation of any transaction. No part of this document may be used by private customers in United Kingdom. All material presented in this report, unless specifically indicated otherwise, is under copyright to Emkay. None of the material, nor its content, nor any copy of it, may be altered in any way, transmitted to, copied or distributed to any other party, without the prior express written permission of EGFSL. All trademarks, service marks and logos used in this report are trademarks or registered trademarks of EGFSL or its Group Companies. The information contained herein is not intended for publication or distribution or circulation in any manner whatsoever and any unauthorized reading, dissemination, distribution or copying of this communication is prohibited unless otherwise expressly authorized. Please ensure that you have read "Risk Disclosure Document for Capital Market and Derivatives Segments" as prescribed by Securities and Exchange Board of India before investing in Indian Securities Market. In so far as this report includes current or historic information, it is believed to be reliable, although its accuracy and completeness cannot be guaranteed.

- This publication has not been reviewed or authorized by any regulatory authority. There is no planned schedule or frequency for updating research publication relating to any issuer.
- Please contact the primary analyst for valuation methodologies and assumptions associated with the covered companies or price targets

Disclaimer for U.S. persons only: This research report is a product of Emkay Global Financial Services Limited (Emkay), which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of Financial Institutions Regulatory Authority (FINRA) or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account. This report is intended for distribution to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on the sender. Further, this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person, which is not the Major Institutional Investor. In reliance on the exemption from registration provided by Rule 15a-6 of the Exchange Act and interpretations thereof by the SEC in order to conduct certain business with Major Institutional Investors.

ANALYST CERTIFICATION BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL)

The research analyst(s) primarily responsible for the content of this research report, in part or in whole, certifies that the views about the companies and their securities expressed in this report accurately reflect his/her personal views. The analyst(s) also certifies that no part of his/her compensation was, is, or will be, directly or indirectly, related to specific recommendations or views expressed in the report. The research analyst (s) primarily responsible of the content of this research report, in part or in whole, certifies that he or his associate does not serve as an officer, director or employee of the issuer or the new listing applicant (which includes in the case of a real estate investment trust, an officer of the management company of the real estate investment trust; and in the case of any other entity, an officer or its equivalent counterparty of the entity who is responsible for the management of the issuer or the new listing applicant). The research analyst(s) primarily responsible for the content of this research report or his associate does not have financial interests in relation to an issuer or a new listing applicant that the analyst reviews. EGFSL has procedures in place to eliminate, avoid and manage any potential conflicts of interests that may arise in connection with the production of research reports. The research analyst(s) responsible for this report operates as part of a separate and independent team to the investment banking function of the EGFSL and procedures are in place to ensure that confidential information held by either the research or investment banking function is handled appropriately. There is no direct link of EGFSL compensation to any specific investment banking function of the EGFSL.

¹ An associate is defined as (i) the spouse, or any minor child (natural or adopted) or minor step-child, of the analyst; (ii) the trustee of a trust of which the analyst, his spouse, minor child (natural or adopted) or minor step-child, is a beneficiary or discretionary object; or (iii) another person accustomed or obliged to act in accordance with the directions or instructions of the analyst.

COMPANY-SPECIFIC / REGULATORY DISCLOSURES BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):

Disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) covered in this report-:

- 1. EGFSL, its subsidiaries and/or other affiliates do not have a proprietary position in the securities recommended in this report as of October 4, 2022
- 2. EGFSL, and/or Research Analyst does not market make in equity securities of the issuer(s) or company(ies) mentioned in this Research Report Disclosure of previous investment recommendation produced:
- 3. EGFSL may have published other investment recommendations in respect of the same securities / instruments recommended in this research report during the preceding 12 months. Please contact the primary analyst listed in the first page of this report to view previous investment recommendations published by EGFSL in the preceding 12 months.
- 4. EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her relative's does not have any material conflict of interest in the securities recommended in this report as of October 4, 2022.
- 5. EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her relative's does not have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the October 4, 2022
- 6. EGFSL, its subsidiaries and/or other affiliates and Research Analyst have not received any compensation in whatever form including compensation for investment banking or merchant banking or brokerage services or for products or services other than investment banking or merchant banking or brokerage services from securities recommended in this report (subject company) in the past 12 months.
- 7. EGFSL, its subsidiaries and/or other affiliates and/or and Research Analyst have not received any compensation or other benefits from securities recommended in this report (subject company) or third party in connection with the research report.
- 8. Securities recommended in this report (Subject Company) has not been client of EGFSL, its subsidiaries and/or other affiliates and/or and Research Analyst during twelve months preceding the October 4, 2022

² Financial interest is defined as interest that are commonly known financial interest, such as investment in the securities in respect of an issuer or a new listing applicant, or financial accommodation arrangement between the issuer or the new listing applicant and the firm or analysis. This term does not include commercial lending conducted at the arm's length, or investments in any collective investment scheme other than an issuer or new listing applicant notwithstanding the fact that the scheme has investments in securities in respect of an issuer or a new listing applicant.

RESTRICTIONS ON DISTRIBUTION

KESTRICTIONS ON L	DOTALDOTTON		
General	This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation.		
Australia	This report is not for distribution into Australia.		
Hong Kong	This report is not for distribution into Hong Kong.		
Indonesia	This report is being distributed in Indonesia by PT DBS Vickers Sekuritas Indonesia.		
Malaysia	This report is not for distribution into Malaysia.		
Singapore	This report is distributed in Singapore by DBS Bank Ltd (Company Regn. No. 16800306E) or DBSVS (Company Regn. No. 1860024G) both of which are Exempt Financial Advisers as defined in the Financial Advisers Act and regulated by the Monetary Authority of Singapore. DBS Bank Ltd and/or DBSVS, may distribute reports produced by its respective foreign entities, affiliates or other foreign research houses pursuant to an agreement under Regulation 32C of the financial Advisers Regulations. Singapore recipients should contact DBS Bank Ltd at 6327 2288 for matters arising from, or in connection with the report.		
Thailand	This report is being distributed in Thailand by DBS Vickers Securities (Thailand) Co Ltd.		
United Kingdom	This report is disseminated in the United Kingdom by DBS Vickers Securities (UK) Ltd, ("DBSVUK"). DBSVUK is authorised and regulated by the Financial Conduct Authority in the United Kingdom. In respect of the United Kingdom, this report is solely intended for the clients of DBSVUK, its respective connected and associated corporations and affiliates only and no part of this document may be (i) copied, photocopied or duplicated in any form or by any means or (ii) redistributed without the prior written consent of DBSVUK. This communication is directed at persons having professional experience in matters relating to investments. Any investment activity following from this communication will only be engaged in with such persons. Persons who do not have professional experience in matters relating to investments should not rely on this communication.		
Dubai International Financial Centre	This research report is being distributed by DBS Bank Ltd., (DIFC Branch) having its office at units 608-610, 6 th Floor, Gate Precinct Building 5, PO Box 506538, Dubai International Financial Centre (DIFC), Dubai, United Arab Emirates. DBS Bank Ltd., (DIFC Branch) is regulated by The Dubai Financial Services Authority. This research report is intended only for professional clients (as defined in the DFSA rulebook) and no other person may act upon it.		
United Arab Emirates	This report is provided by DBS Bank Ltd (Company Regn. No. 196800306E) which is an Exempt Financial Adviser as defined in the Financial Advisers Act and regulated by the Monetary Authority of Singapore. This report is for information purposes only and should not be relied upon or acted on by the recipient or considered as a solicitation or inducement to buy or sell any financial product. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situation, or needs of individual clients. You should contact your relationship manager or investment adviser if you need advice on the merits of buying, selling or holding a particular investment. You should note that the information in this report may be out of date and it is not represented or warranted to be accurate, timely or complete. This report or any portion thereof may not be reprinted, sold or redistributed without our written consent.		
United States	DBSVUSA did not participate in its preparation. The research analyst(s) named on this report are not registered as research analysts with FINRA and are not associated persons of DBSVUSA. The research analyst(s) are not subject to FINRA Rule 2241 restrictions on analyst compensation, communications with a subject company, public appearances and trading securities held by a research analyst. This report is being distributed in the United States by DBSVUSA, which accepts responsibility for its contents. This report may only be distributed to Major U.S. Institutional Investors (as defined in SEC Rule 15a-6) and to such other institutional investors and qualified persons as DBSVUSA may authorize. Any U.S. person receiving this report who wishes to effect transactions in any securities referred to herein should contact DBSVUSA directly and not its affiliate.		
Other jurisdictions	In any other jurisdictions, except if otherwise restricted by laws or regulations, this report is intended only for qualified, professional, institutional or sophisticated investors as defined in the laws and regulations of such jurisdictions.		

Emkay Global Financial Services Ltd.

CIN - L67120MH1995PLC084899

7th Floor, The Ruby, Senapati Bapat Marg, Dadar - West, Mumbai - 400028. India Tel: +91 22 66121212 Fax: +91 22 66121299 Web: www.emkayglobal.com